A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (1,304 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lung cancersmallcell lungnonsquamous
  Phrases that lowered it: kgm2and safetyefficacy andday
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past termination rate: 12.1% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 189 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 282 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 19.0% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Minimum age: 70 (lowers risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 6120 (lowers risk) · Drug's FDA history
• Keywords listed: 0 (lowers risk) · Design
• Drug's FAERS reports before start: 26242 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine NCT00753714 · started 2008 · scored riskier than 97% of active trials completed
• Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC NCT03717155 · started 2018 · scored riskier than 33% of active trials completed
• A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer. NCT00700180 · started 2008 · scored riskier than 27% of active trials completed
• Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients NCT00754364 · started 2008 · scored riskier than 89% of active trials terminated
• Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC NCT02175381 · started 2011 · scored riskier than 92% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.